• Explore /
  • Poster
  • / Crizotinib in <em>ROS1</em>-rearranged lung cancer (EUCROSS): Updated overall survival.

Crizotinib in ROS1-rearranged lung cancer (EUCROSS): Updated overall survival.

Abstract Poster

Authors

null

Sebastian Yves Friedrich Michels

University of Cologne, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Lung Cancer Group, Cologne, Germany

Sebastian Yves Friedrich Michels , Jeremy Franklin , Bartomeu Massuti , Martin Sebastian , Enriqueta Felip , Christian Grohé , Delvys Rodriguez-Abreu , Helge Bischoff , Enric Carcereny , Jesús Corral , Amelia Insa , Martin Reck , Sacha Rothschild , Mariano Provencio , Matthias Scheffler , Martin Hellmich , Lucia Nogova , Reinhard Büttner , Rafael Rosell , Juergen Wolf

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02183870

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9078)

DOI

10.1200/JCO.2022.40.16_suppl.9078

Abstract #

9078

Poster Bd #

65

Abstract Disclosures

Similar Posters

First Author: Yosuke Kagawa

First Author: Vineeth Tatineni

Poster

2020 ASCO Virtual Scientific Program

Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.

Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.

First Author: D. Ross Camidge

First Author: Sebastian Yves Friedrich Michels